March 26, 2020: Lopinavir/ritonavir falls short against COVID-19; impact of PrEP scale-up on HIV diagnoses; long-term cost-effectiveness of various HIV interventions; disparities in virologic suppression among young people.
The findings will help providers manage patients who have known or potential resistance to NRTIs, but who we want to place on a simplified antiretroviral regimen.
In our final installment of 2017, we intermingle forward-looking research with some retrospective analysis. We begin our four-study tour by joining researchers in Tennessee for an exercise in HIV outbreak prediction.
Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by? Researcher Charles W. Flexner recently addressed several common myths.
Women on Lopinavir/Ritonavir-Based Regimens at Conception at Higher Risk of Preterm Delivery in UK Study
HIV-positive pregnant women receiving lopinavir/ritonavir-based regimens were at higher risk of preterm delivery compared with those on NNRTI-based regimens.
Each additional year of tenofovir disoproxil fumarate, ritonavir-boosted atazanavir or lopinavir was independently linked to higher incidence of chronic kidney disease in a 23,905-person cohort with initially normal renal function.
On May 21, the U.S. Food and Drug Administration tentatively approved lopinavir/ritonavir 40/10-mg pellets for infants and young children less than 3 years old.
Lopinavir/Ritonavir Superior to Nevirapine in Children Over 3 Years Old: IMPAACT P1060 Study Results
Long-term virologic suppression was superior in children receiving lopinavir/ritonavir-based antiretroviral therapy compared with nevirapine-based regimens at five-year follow up in the IMPAACT P1060 trial.
Once potent combination therapy for HIV (commonly called ART or HAART) is initiated, several clinical trials have found that bone mineral density tends to decrease, usually between 2% and 6%, and then stabilize. The reasons for this initial decrease ...
A recent study revealed a surprising result: For the first time ever, an HIV treatment regimen consisting of two drugs was found to work just as well as a three-drug regimen.